UCB、抗リン脂質抗体症候群の妊婦を対象とした「CIMZIA」にFDAブレイクスルーセラピー指定──IMPACT試験の結果と臨床的位置づけを整理
stellanews.life/technology/1... #CIMZIA #IMPACT試験

FDA Grants Breakthrough Therapy Status to UCB's Cimzia in High-Risk APS Pregnancy UCB received FDA Breakthrough Therapy Designation for studying Cimzia in...

https://www.narrowit.com/news/ucb-cimzia-fda-breakthrough-therapy-aps-pregnancy-2026-09-10
#UCB #Cimzia #FDA #AntiphospholipidSyndrome

UCB Achieves FDA Breakthrough Therapy Designation for CIMZIA in Addressing Pregnancy Risks in APS #USA #Atlanta #FDA #APS #CIMZIA